Riskpilot← Back to searchSign inGet full accessMyCural Therapeutics AB
ABActiveOrg 5593950164Sidenvävargatan 17Research and experimental development on natural sciences and engineering · NACE 7210Est. 202210-19 employees
Revenue 2024
SEK 799K
+3096% vs 2023
EBITDA margin
-964.1%
-30% vs 2023
Equity ratio
73.1%
Financial strength
Net profit 2024
SEK -7,6M
-30% vs 2023
| Revenue | SEK 799K | +3096% |
| EBITDA | SEK -7,7M | -30% |
| Net profit | SEK -7,6M | -30% |
| Total assets | SEK 5,8M | +0% |
| Equity | SEK 4,2M | -8% |
| Employees | — | — |
Legal name
MyCural Therapeutics AB
Org number
5593950164
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
5 september 2022
Share capital
SEK 35 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolagets verksamhet ska vara att utveckla läkemedel och behandlingsterapier för cancer, vilket innebär att driva egen forskningsverksamhet, licensiera patent och teknologier, tillhandahålla analys- och konsulttjänster i samband med licensaffärer, samt idka därmed förenlig verksamhet.
Address
Sidenvävargatan 17
Email
alina.castell@mycural.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 25 | 799 |
| Staff expenses | — | — |
| EBITDA | −5 907 | −7 703 |
| Depreciation & amort. | −0 | −0 |
| EBIT | −5 907 | −7 703 |
| Net financials | 46 | 73 |
| Profit before tax | −5 862 | −7 630 |
| Tax | −0 | −0 |
| Net profit | −5 862 | −7 630 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 5 815 | 5 799 |
| Equity | 4 598 | 4 240 |
| Long-term debt | 0 | 0 |
| Short-term debt | 1 217 | 1 559 |
| Total debt | 1 217 | 1 559 |
EBITDA margin
-964.1%
This company
15.8%
Market median
-6202% vs market
20232024
Equity ratio
73.1%
This company
38.2%
Market median
+91% vs market
20232024
Return on equity
-180.0%
This company
18.4%
Market median
-1078% vs market
20232024
Net profit margin
-954.9%
This company
8.1%
Market median
-11889% vs market
20232024
Asset turnover
0.14×
This company
1.12×
Market median
-88% vs market
20232024
Debt / equity
0.37×
This company
0.62×
Market median
+40% vs market
20232024
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
AA Chief Executive Officer | Chief Executive Officer | 2022 |
SA Chief Auditor | Chief Auditor | 2025 |
LO Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (1) | ||
EC Audit | Audit | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Former (3) | ||
| Board of Directors | 2022 – 2025 | |
| Chairman | 2022 – 2025 | |
| Board of Directors | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MyCural Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Alina Andrea Viktoria Castell | Chief Executive Officer | 0 companies |
| Stéphanie Anna Chantal Ljungberg | Chief Auditor | 0 companies |
| Eva Carina Sternesjö | Audit | 0 companies |
| Lars-Gunnar Olof Larsson | Chief Executive Officer | 0 companies |
| Ylva Gunilla Ekström | Board of Directors | 0 companies |
| Lena Ann-Charlotte Rosendahl | Chairman | 0 companies |
| Gunhild Maria Selander Sunnerhagen | Board of Directors | 0 companies |
| Jan Håkan Berglöf | Deputy Board Member | 0 companies |
| Pernilla Helena Sandwall | Board of Directors | 0 companies |
| Nina Teerés Herne | Chairman | 0 companies |
| Per Källblad | Board of Directors | 0 companies |
| Klas Gösta Wiman | Board of Directors | 0 companies |